Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Public ClinicalTrials.gov record NCT04589845. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.
Study identification
- NCT ID
- NCT04589845
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 920 participants
Conditions and interventions
Conditions
Interventions
- Entrectinib Drug
- Alectinib Drug
- Atezolizumab Drug
- Ipatasertib Drug
- Trastuzumab emtansine Drug
- Inavolisib Drug
- Belvarafenib Drug
- Pralsetinib Drug
- Divarasib Drug
- Camonsertib Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 18, 2021 (Actual)
- Primary completion
- Sep 25, 2032 (Estimated)
- Completion
- Sep 25, 2032 (Estimated)
- Last update posted
- Sep 4, 2026
2021 – 2032
United States locations
- U.S. sites
- 32
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Western Regional Medical Center at Cancer Treatment Centers of America | Goodyear | Arizona | 85338 | — |
| Kaiser Permanente Los Angeles | Los Angeles | California | 90027 | — |
| USC Norris Cancer Center | Los Angeles | California | 90033 | — |
| Hoag Memorial Hospital | Newport Beach | California | 92658 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| University Cancer & Blood Center, LLC | Athens | Georgia | 30607 | — |
| St. Alphonsus | Boise | Idaho | 83706 | — |
| Midwestern Regional Med Center | Zion | Illinois | 60099 | — |
| Horizon Oncology Research, Inc. | Lafayette | Indiana | 47905 | — |
| Maryland Hematology & Oncology. P.A. | Silver Spring | Maryland | 20904 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Metro-Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota | 55416 | — |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana | Billings | Montana | 59102 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| University of New Mexico | Albuquerque | New Mexico | 87131 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 11101 | — |
| Montefiore Einstein Center for Cancer Care | The Bronx | New York | 10461 | — |
| Barrett Cancer Center | Cincinnati | Ohio | 45219 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| Consultants in Medical Oncology and Hematology | Broomall | Pennsylvania | 19008 | — |
| Alliance Cancer Specialists | Horsham | Pennsylvania | 19044 | — |
| Virginia Cancer Specialists - Leesburg | Leesburg | Pennsylvania | 20176 | — |
| Cancer Treatment Centers of America | Philadelphia | Pennsylvania | 19124 | — |
| The West Clinic | Germantown | Tennessee | 38138 | — |
| St. Jude Children'S Research Hospital | Memphis | Tennessee | 38105 | — |
| Texas Oncology - Central South | Austin | Texas | 78731 | — |
| Mary Crowley Medical Research Center | Dallas | Texas | 75230 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology- Northeast Texas | Tyler | Texas | 75702 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
| Froedtert and The Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04589845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04589845 live on ClinicalTrials.gov.